Get the Stockscreener App
3.73
5.57%
-0.22
After Hours:
3.42
-0.31
-8.31%
Eagle Pharmaceuticals Inc stock is traded at $3.73, with a volume of 145.90K.
It is down -5.57% in the last 24 hours and down -27.43% over the past month.
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.
See More
Previous Close:
$3.95
Open:
$3.95
24h Volume:
145.90K
Relative Volume:
1.08
Market Cap:
$48.20M
Revenue:
$257.55M
Net Income/Loss:
$11.95M
P/E Ratio:
4.0989
EPS:
0.91
Net Cash Flow:
$-9.39M
1W Performance:
-4.24%
1M Performance:
-27.43%
6M Performance:
-28.82%
1Y Performance:
-76.35%
1-Day Range:
$3.5001
$3.98
1-Week Range:
$3.5001
$4.169
52-Week Range:
$3.2101
$15.70
Eagle Pharmaceuticals Inc Stock (EGRX) Company Profile
Name
Eagle Pharmaceuticals Inc
Sector
Phone
201-326-5300
Address
50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE, NJ
Eagle Pharmaceuticals Inc Stock (EGRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-01-18 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Mar-21-18 | Reiterated | Mizuho | Underperform |
| Nov-09-17 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-06-17 | Reiterated | Mizuho | Underperform |
| Jul-27-17 | Reiterated | Mizuho | Underperform |
| Jul-27-17 | Reiterated | RBC Capital Mkts | Outperform |
| May-09-17 | Reiterated | RBC Capital Mkts | Outperform |
| Jan-09-17 | Downgrade | Mizuho | Neutral → Underperform |
| Nov-16-16 | Downgrade | Mizuho | Buy → Neutral |
| Nov-03-16 | Upgrade | Mizuho | Neutral → Buy |
| Nov-03-16 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-26-16 | Reiterated | Mizuho | Buy |
| Aug-16-16 | Reiterated | Mizuho | Neutral |
| Jun-20-16 | Downgrade | Mizuho | Buy → Neutral |
| May-10-16 | Reiterated | RBC Capital Mkts | Outperform |
| Mar-18-16 | Reiterated | Mizuho | Buy |
| Feb-26-16 | Reiterated | Mizuho | Buy |
| Dec-09-15 | Initiated | Mizuho | Buy |
| Jul-29-15 | Reiterated | Piper Jaffray | Overweight |
View All
Eagle Pharmaceuticals Inc Stock (EGRX) Latest News
173,365 Shares in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Bought by Perceptive Advisors LLC - MarketBeat
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com - Defense World
Bendamustine Market 2024 Growth Potential, Manufacturers, Production, Revenue and Forecast 2032 Teva, Eisai, Eagle Pharmaceuticals, MundiPharma – Cauverynews - Cauverynews
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com - MarketBeat
Emergent Sinks on New Orders for Smallpox, Mpox Vaccine - Baystreet.ca
Emergent Biosolutions Shares Rise 16% on Orders Secured for Smallpox, Monkeypox Vaccines - MarketWatch
Fidelis Capital Partners LLC Purchases New Shares in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
Acadian Asset Management LLC Sells 26,056 Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
First Eagle Investment Management LLC Grows Position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) - Defense World
Beta Blockers Global Market Report 2024: Size, Growth Rate, and Segments - WhaTech
From Rs 5.97 to Rs 47.25 per share in just 137 days: Debt-free multibagger penny stock hit back-to-back upper circuits & 52-week highs; Here’s why! - Dalal Street Investment Journal
StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX) - Defense World
Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com - MarketBeat
LSV Asset Management Reduces Stake in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
Los Angeles Capital Management LLC Cuts Stock Position in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
StockNews.com Initiates Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX) - MarketBeat
StockNews.com Initiates Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX) - Defense World
Eagle Pharmaceuticals receives another delisting notice - NJBIZ
Vasopressin for Vasoplegic Shock Market: Advances in Vasopressin - WICZ
Is Eagle Pharmaceuticals Inc (EGRX) a good investment opportunity? - US Post News
Is Eagle Pharmaceuticals Inc (EGRX) positioned for future growth? - SETE News
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by StockNews.com - MarketBeat
Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com - Defense World
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Short Interest Update - MarketBeat
Eagle Pharmaceuticals faces potential Nasdaq delisting - Investing.com India
Eagle Pharmaceuticals faces potential Nasdaq delisting - Investing.com
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq - ForexTV.com
Eagle Pharmaceuticals Struggles with Financial Compliance and Nasdaq Listing - TipRanks
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq - StockTitan
Eagle Pharmaceuticals (NASDAQ:EGRX) Now Covered by Analysts at StockNews.com - Defense World
Investigation announced for Long-Term Investors in shares of Eagle Pharmaceuticals, Inc. (NADAQ: EGRX) - openPR
Price T Rowe Associates Inc. MD Purchases Shares of 15,748 Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
Vanguard Group Inc. Acquires 2,630 Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
Price T Rowe Associates Inc. MD Takes Position in Sagimet Biosciences Inc. (NASDAQ:SGMT) - Defense World
Eagle Pharmaceuticals (NASDAQ:EGRX) Stock Price Crosses Below Two Hundred Day Moving Average of $4.98 - Defense World
Eagle Pharmaceuticals (NASDAQ:EGRX) Shares Cross Below Two Hundred Day Moving Average of $4.98 - MarketBeat
Eagle Pharmaceuticals (NASDAQ:EGRX) Research Coverage Started at StockNews.com - MarketBeat
Eagle Pharmaceuticals (NASDAQ:EGRX) Research Coverage Started at StockNews.com - Defense World
StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX) - MarketBeat
Eagle Pharmaceuticals secures Nasdaq listing extension - Investing.com
Eagle Pharmaceuticals secures Nasdaq listing extension By Investing.com - Investing.com Canada
Jacobs Levy Equity Management Inc. Makes New $64,000 Investment in Lyell Immunopharma, Inc. (NASDAQ:LYEL) - Defense World
Eagle Pharmaceuticals (NASDAQ:EGRX) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
Acadian Asset Management LLC Sells 235,109 Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
Acadian Asset Management LLC Sells 235,109 Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - MarketBeat
Acadian Asset Management LLC Reduces Stock Holdings in Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - MarketBeat
(EGRX) Proactive Strategies - Stock Traders Daily
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) Shares Sold by BNP Paribas Financial Markets - Defense World
Eagle Pharmaceuticals (NASDAQ:EGRX) Receives New Coverage from Analysts at StockNews.com - Defense World
Headlands Technologies LLC Purchases 2,861 Shares of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) - Defense World
Antiemetics Drugs Market Size & Share Report, 2024 – 2032 - Global Market Insights
Eagle Pharmaceuticals Inc Stock (EGRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.23%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):